❖ Watson Bio's mRNA vaccine third dose booster needle approved for Phase III clinical trials
On the 10th, the phase III clinical trial of Watson Biological mRNA new crown vaccine sequentially vaccinated inactivated new crown vaccine for people over 18 years old was approved by the state. (Sina Pharmaceutical News)
❖ Yuce Biologics, a genetic testing service provider of precision immunotherapy for tumors, completed a round of financing of about 100 million yuan
On November 11, Shenzhen Yuce Biotechnology Co., Ltd. announced the completion of a C+ round of financing of nearly 100 million yuan, which was exclusively invested by Shenzhen Zizi Wealth.
Yuce Bio is a tumor precision immunotherapy gene testing and big data analysis platform, providing genetic testing and analysis services to guide and assist in disease diagnosis and medication treatment. Launched genetic testing products, has reached cooperation with more than 20 medical institutions to provide immunotherapy genetic testing and interpretation services. (Zero One Finance)
❖ With the most comprehensive gene editing tools in the industry, Zhang Fengxin Company has received more than $200 million in financing
Gene-editing company Arbor Biotechnologies announced the completion of a $215 million Series B funding round. Arbor plans to use part of this funding to advance its pilot program for liver and central nervous system (CNS) diseases to the clinical stage.
Founded in 2016 by Professor Feng Zhang, a pioneer in CRISPR gene editing technology, Arbor announced the completion of a $15.6 million Series A round of funding a year later. Public information shows that the just-announced Series B funding round is more than 13 times more funded than the Series A round, led by Temasek, Ally Bridge Group and TCG Crossover.
Arbor also plans to use some of the proceeds to further develop its gene-editing technology platform, which applies a "toolbox" based on the CRISPR Genome Editor and technologies such as artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, with the goal of identifying "influential" peptides, proteins, and enzymes. (Shenghui)
❖ Genentech and Novome develop microbiome therapies
On November 10, Novome Biotechnologies ("Novome") announced a multi-year research collaboration and licensing agreement with Genentech, a subsidiary of Roche Corporation, to develop therapeutic engineered bacteria colonization therapies for human intestinal diseases using Novome's proprietary platform of genetically engineered microbials (GEMMs). The press release shows that Novome will receive an advance payment of $15 million, and Novome is also eligible for potential milestone payments of up to $590 million based on the achievement of pre-specified development and commercial milestones. (Instant Medicine Smell)
❖ BGI Liu Xin et al. team plotted a complete map of chickpea genetic variation
On November 10, BGI Liu Xin and Rajeev Varshney, an international crop research center for the semi-arid tropics, published a research paper titled "A chickpea genetic variation map based on the sequencing of 3,366 genomes" on Nature Online, which showed a detailed variation map of 3,171 cultivars and 195 wild varieties. Provides a publicly available resource for chickpea genomics research and breeding.
The study analyzed chromosomal fragments and genes that show selection characteristics during domestication, migration, and modification. The chromosomal locations of harmful mutations that lead to limited genetic diversity and reduced adaptability are identified in the fine germplasm. （iNature）
All reprinted articles in this number are for the purpose of transmitting more information, and clearly indicate the source and author, and media or individuals who do not wish to be reprinted can contact us, and we will delete them immediately. All articles represent the views of the author only and do not represent the position of the Party.